

boston.com Find your next job.
MONSTER SEARCH LISTINGS ▶

Markets MA Stock Indexes Stocks Funds Sectors Tools
 Overview Market News Market Videos Currencies International
 Treasury & Bonds

GET QUOTE Search InvestCenter ▶

Recent Quotes ▶ My Watchlist ▶ Indicators ▶ Local Stocks ▶

By: **DSG Inc.** via **Business Wire News Releases**

September 14, 2009 at 07:00 AM EDT

Cipher Uses DSG's EDC in Effort to Give Hope to Severe Acne Sufferers



dsgedc⁺
Electronic Data Capture

DSG Inc., an industry leader in clinical trial data collection and management, today announced that Cipher Pharmaceuticals (**TSX:DND**) is using electronic data capture (EDC) software and data management services from DSG. Cipher is using DSG's eCaseLink™ for its Phase 3 dermatology study on its new compound for the treatment of severe acne. Cipher's new treatment offers new hope for patients with severe inflammatory or recalcitrant nodular acne who are unresponsive to conventional therapy.

DSG's eCaseLink™ makes it possible to merge and analyze a highly complex array of widely varied data across a large patient base. Cipher is using DSG's integrated data management services for all aspects of database design, usage, freeze, lock and archiving at 50 sites throughout the U.S. and Canada with 800 patients estimated to complete the study over an anticipated 18 month period.

"As we move forward with our clinical trial process it is essential that we have the latest in EDC and data management technology that reduces overall trial costs and improves data quality," said Jason A. Gross, Pharm.D., Vice President of Scientific Affairs, Cipher Pharmaceuticals. "DSG's EDC offering in combination with integrated data management helps us meet our objectives to bring the latest therapies to market."

"DSG is proud to be supporting Cipher Pharmaceuticals through its critical Phase 3 study," said Tony Varano, CEO, DSG, Inc. "We are confident that our integrated approach to EDC and data

management will reap tangible benefits in controlling costs and ensuring study success at Cipher, putting a new face on a proven treatment for severe acne.”

About DSG

DSG Inc., ranked no. 82 on the Inc. 500, supports clinical trial data collection and management with innovative technology solutions including Electronic Data Capture with specialized Clinical Data Management services, IWRS (web-based patient randomization and drug/device supply management), Clinical Trial Management Systems and digital on-demand Case Report Form publishing management software. DSG's products allow user-friendly, accurate and efficient data capture at any investigator site regardless of the technological infrastructure. DSG has successfully supported over 1000 clinical trials for more than 325 companies at over 18,000 sites in over 68 countries. Founded in 1992, DSG is a global company headquartered in Malvern, Pa., with additional offices in the U.S., Japan and India. For more information, please visit www.dsg-us.com.

All products and services mentioned in this announcement are the property of their respective owners.

Contacts:

DSG Inc.
David Grace, +1 484-913-0210 x109
dgrace@dsg-us.com

0 Comments

FinancialContent

Login ▾

Sort by Best ▾

Recommend **Share**



Start the discussion...

Be the first to comment.

Related Stocks:

 **CIPHER PHARM**

invest 

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.



Markets are closed on certain holidays. [Stock Market Holiday List](#)
By accessing this page, you agree to the following
[Privacy Policy](#) and [Terms and Conditions](#).
[Press Release Service](#) provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates



Ad Choices | ©2014 Boston.com